吡格列酮对早期糖尿病肾病的临床观察  

Clinical Observation of Pioglitazone in Treating Diabetic Nephropathy

作　　者：赵学兰[1] 李香玲[1] 张琳琳[1] 李凯[1] 

机构地区：[1]潍坊医学院附属医院肾内科,山东潍坊261031

出　　处：《潍坊医学院学报》2009年第5期366-367,共2页Acta Academiae Medicinae Weifang

摘　　要：目的观察吡格列酮对早期糖尿病肾病(DN)尿白蛋白排泄率(UAER)的影响。方法 46例早期DN患者,随机分为治疗组、对照组,各23例。在常规降糖、降压药治疗的基础上,治疗组加用吡格列酮30mg/d口服,连用12周。观察治疗前后UAER、糖化血红蛋白(HbA1C)、尿素氮(BUN)、血肌酐(SCr)、内生肌酐清除率(Ccr)的变化。结果①治疗组治疗后UAER、HbA1C明显下降,与治疗前比较差异有显著性(P<0.01),与对照组比较差异有显著性(P<0.05);②两组治疗前后BUN,SCr,Ccr差异无显著性(P>0.05)。结论吡格列酮能降低早期糖尿病肾病患者的UAER,并有显著降低血糖、保护肾脏的作用。Objective To observe the effects of pioglitazone on Urinaryalbumin excretion rate（ UAER） in patients with early diabetic nephropathy （ DN ） . Methods Forty-six patients of type 2 diabetic with early DN were randomly divided into control group and treated group. UAER, giycosylated hemoglobin （ GHb, HbA1C ） , blood urea nitrogen （BUN ） ,surem creatinine（ SCr1 ,and endogenous creatinine clearance rate（Ccrl were compared between two groups before treatment and eight weeks after treatment. Results After treatment,UAER, HbA1C decreased significantly in treated group（P 〈 0.01） ;There were significant differences between treatment group and control group（P 〈 0.05 ） ;While no significant decrease of BUN, Ccr and SCr was found in both groups during the follow-up （ P 〉 0.05）. Conclusion Pioglitazone can decrease proteinuria and improve renal function of the patients with early DN.

关 键 词：糖尿病肾病 吡格列酮 尿白蛋白排泄率 

分 类 号：R587.2[医药卫生—内分泌]